OPEN SESSIONS

Venue: Hochelaga II
Date: Saturday, May 1st 2011
Time: 8:30 a.m. – 12:00 p.m.
Chair: Dr. Warren Mason

8:30 am  WELCOME AND INTRODUCTIONS  W. Mason

NEW CONCEPTS/PROPOSALS FOR ENDORSEMENT

8:35 am  ECOG E3F05: Phase III study of radiotherapy +/- temozolomide for symptomatic or progressive low-grade gliomas  D. Schiff (ECOG)

9:00 am  NCCTG N107C: A phase III trial of post-surgical stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for resected metastatic brain disease  P. Brown (NCCTG)

COMPLETED STUDIES

9:30 am  IND.162: A Phase I/II study of Temozolomide and RAD001c in Patients with Malignant Glioblastoma Multiforme
Final report and manuscript status  W. Mason

TRIALS CLOSED TO ACCRUAL

9:40 am  CE5 (EORTC 22033-26033): Primary Chemotherapy with Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study  W. Mason

CE.5S: The Socio/behavioural Effects of Primary Chemotherapy with Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study  A. Leis & M. Parkinson
ACTIVELY ACCRUING TRIALS

9:50 am  **CE.6**: A Randomized Phase III Study of Temozolomide and Short-Course Radiation versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients  
N. Laperriere & J. Perry

10:00 am  COFFEE BREAK

10:15 am  **CEC.1 (EORTC 26053_22054)**: Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19Q Deleted Anaplastic Glioma.  
The CATNON Intergroup Trial  
W. Mason & C. O’Callaghan

10:30 am  **CEC.2 (NCCTG N0577)**: Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma (CODEL Trial)  
G. Cairncross & C. O’Callaghan

10:45 am  **IND.204**: PX866 in Recurrent GBM  
M. Pitz

SPECIAL SESSION - TERRY FOX RESEARCH INSTITUTE (TFRI) PROPOSAL: THERAPEUTIC TARGETING OF GBM

11:00 am  Project Overview  
G. Cairncross

11:10 am  Translational Research Program  
A. Luchman

11:40 am  Role of NCIC CTG Brain and IND sites in conducting early phase clinical trials of promising new drugs for GBM  
E. Eisenhauer & W. Mason

12:00 p.m.  **Closing Remarks**

Learning Objectives

- To understand and address, through clinical and translational research, the disease burden associated with CNS malignancies in Canada.
- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to CNS malignancies.
- To cite and analyze recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group relevant to CNS malignancies.
- To understand and apply new clinical trial methodologies in the field of clinical research in CNS malignancies.